Last reviewed · How we verify

NCT05819034

Conservative Management for Adolescent Idiopathic Scoliosis

Recruiting now NA Last updated 15 September 2025
What this trial tests

NA trial testing Scoliosis-Specific Exercise Program in Scoliosis; Adolescence in 60 participants. Currently enrolling.

Timeline
1 February 2024
Primary endpoint
20 December 2025
20 December 2025

Quick facts

Lead sponsorUmm Al-Qura University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date1 February 2024
Primary completion20 December 2025
Estimated completion20 December 2025
Sites1 location across Saudi Arabia

Drugs / interventions tested

Conditions studied

Sponsor

Umm Al-Qura University

Who can join

Adults 10 to 17, any sex, with Scoliosis; Adolescence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Idiopathic scoliosis is a living problem that resists correction. The underlying cause of the such disorder is unknown but directed more toward muscular disorders. However recent clinical observation showed a possible neuromuscular compromise early in those patients. The main purpose of this study is to develop a treatment procedure to correct the degree of bony curvature in patients with Idiopathic scoliosis through developing a neuromuscular corrective approach that might be a more effective conservative treatment protocol for such disorder.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Scoliosis; Adolescence

Currently open trials in the same condition.

Other Umm Al-Qura University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05819034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing